Annual Cash & Cash Equivalents
$3.71 M
+$2.35 M+172.35%
December 31, 2023
Summary
- As of February 7, 2025, ENTO annual cash & cash equivalents is $3.71 million, with the most recent change of +$2.35 million (+172.35%) on December 31, 2023.
- During the last 3 years, ENTO annual cash & cash equivalents has fallen by -$2.35 million (-38.77%).
- ENTO annual cash & cash equivalents is now -55.00% below its all-time high of $8.25 million, reached on December 1, 2021.
Performance
ENTO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$366.80 K
-$295.70 K-44.63%
September 1, 2024
Summary
- As of February 7, 2025, ENTO quarterly cash and cash equivalents is $366.80 thousand, with the most recent change of -$295.70 thousand (-44.63%) on September 1, 2024.
- Over the past year, ENTO quarterly cash and cash equivalents has dropped by -$3.35 million (-90.12%).
- ENTO quarterly cash and cash equivalents is now -96.95% below its all-time high of $12.03 million, reached on March 1, 2021.
Performance
ENTO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ENTO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +172.3% | -90.1% |
| 3 y3 years | -38.8% | -82.2% |
| 5 y5 years | +233.1% | -76.3% |
ENTO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -55.0% | +172.3% | -95.5% | at low |
| 5 y | 5-year | -55.0% | +2011.4% | -97.0% | +108.7% |
| alltime | all time | -55.0% | +3815.4% | -97.0% | +185.4% |
Entero Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $366.80 K(-44.6%) |
| Jun 2024 | - | $662.50 K(-80.7%) |
| Mar 2024 | - | $3.43 M(-7.5%) |
| Dec 2023 | $3.71 M(+172.3%) | $3.71 M(+12.7%) |
| Sep 2023 | - | $3.29 M(+166.3%) |
| Jun 2023 | - | $1.24 M(-40.1%) |
| Mar 2023 | - | $2.06 M(+51.5%) |
| Dec 2022 | $1.36 M(-83.5%) | - |
| Dec 2022 | - | $1.36 M(-17.7%) |
| Sep 2022 | - | $1.66 M(+43.5%) |
| Jun 2022 | - | $1.16 M(-79.7%) |
| Mar 2022 | - | $5.70 M(-31.0%) |
| Dec 2021 | $8.25 M(+36.1%) | $8.25 M(+14.4%) |
| Sep 2021 | - | $7.21 M(-10.7%) |
| Jun 2021 | - | $8.07 M(-32.9%) |
| Mar 2021 | - | $12.03 M(+98.4%) |
| Dec 2020 | $6.06 M | $6.06 M(-46.7%) |
| Sep 2020 | - | $11.37 M(+1054.3%) |
| Jun 2020 | - | $984.90 K(-39.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $1.63 M(+827.2%) |
| Dec 2019 | $175.80 K(-84.2%) | $175.80 K(-88.7%) |
| Sep 2019 | - | $1.55 M(+18.2%) |
| Jun 2019 | - | $1.31 M(+216.7%) |
| Mar 2019 | - | $413.90 K(-62.9%) |
| Dec 2018 | $1.11 M(+94.3%) | $1.11 M(-74.8%) |
| Sep 2018 | - | $4.43 M(-40.3%) |
| Jun 2018 | - | $7.42 M(+1191.6%) |
| Mar 2018 | - | $574.50 K(+0.2%) |
| Dec 2017 | $573.50 K(-67.7%) | $573.50 K(-80.5%) |
| Sep 2017 | - | $2.95 M(-23.0%) |
| Jun 2017 | - | $3.83 M(+619.8%) |
| Mar 2017 | - | $531.90 K(-70.0%) |
| Dec 2016 | $1.77 M(+204.9%) | $1.77 M(+1280.2%) |
| Sep 2016 | - | $128.50 K(-90.5%) |
| Jun 2016 | - | $1.35 M(+701.5%) |
| Mar 2016 | - | $169.00 K(-70.9%) |
| Dec 2015 | $581.70 K(+513.6%) | $581.70 K |
| Dec 2014 | $94.80 K | - |
FAQ
- What is Entero Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Entero Therapeutics?
- What is Entero Therapeutics annual cash & cash equivalents year-on-year change?
- What is Entero Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Entero Therapeutics?
- What is Entero Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Entero Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ENTO is $3.71 M
What is the all time high annual cash & cash equivalents for Entero Therapeutics?
Entero Therapeutics all-time high annual cash & cash equivalents is $8.25 M
What is Entero Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ENTO annual cash & cash equivalents has changed by +$2.35 M (+172.35%)
What is Entero Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ENTO is $366.80 K
What is the all time high quarterly cash and cash equivalents for Entero Therapeutics?
Entero Therapeutics all-time high quarterly cash and cash equivalents is $12.03 M
What is Entero Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ENTO quarterly cash and cash equivalents has changed by -$3.35 M (-90.12%)